Company Filing History:
Years Active: 1995-1996
Title: **Barry J Kobrin: Pioneer in Cancer Monoclonal Antibodies**
Introduction
Barry J Kobrin, an innovative inventor based in Silver Spring, MD, has made significant contributions to the field of cancer research through his development of groundbreaking monoclonal antibodies. With a total of two patents to his name, Kobrin has focused his efforts on creating diagnostic and therapeutic tools to combat human cancers.
Latest Patents
Kobrin's latest patents include the "Tumor Associated Monoclonal Antibody 123AV16," which pertains to transformed B-cell lines derived from peripheral blood B-cells of cancer patients immunized with autologous tumor antigens. This invention represents a significant advancement in the use of monoclonal antibodies for both diagnostic and therapeutic applications in human cancers. His other notable patent is for "Tumor Associated Monoclonal Antibodies," specifically the monoclonal antibody 88BV59. This antibody also stemmed from B-cell lines derived from similarly immunized cancer patients and holds promise for diagnostics and therapeutic interventions.
Career Highlights
Throughout his career, Barry J Kobrin has worked with prestigious companies such as Akzo Nobel N.V. and Akzo N.V., where his expertise in immunology and biochemistry has propelled advancements in cancer treatments. His work has not only advanced the scientific community's understanding of monoclonal antibodies but has also brought novel solutions to the healthcare industry.
Collaborations
Kobrin has collaborated with esteemed colleagues, including Martin V Haspel and Michael G Hanna, Jr. These partnerships have facilitated a shared vision for developing innovative approaches to treating cancer, underscoring the importance of collaboration in the advancement of scientific research.
Conclusion
In conclusion, Barry J Kobrin stands out as a passionate inventor whose work in monoclonal antibodies is making strides in cancer diagnostics and therapy. His dedication to innovation and collaboration exemplifies the spirit of scientific advancement, providing hope for improved cancer treatment options in the future. Through his patents and professional relationships, Kobrin continues to influence the landscape of cancer research, paving the way for further breakthroughs.